2024 annual financial data
ProQR Therapeutics 2024 Operating cash flow growth
Direct answer
Operating cash flow growth was -268.89%.
Operating income was -30,472,000 EUR and net income was -27,763,000 EUR.
Operating cash flow was -36,393,000 EUR.
Get free ProQR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 18,905,000 EUR
- Operating income
- -30,472,000 EUR
- Net income
- -27,763,000 EUR
- Operating cash flow
- -36,393,000 EUR